US2002006409A1PendingUtilityA1

Composition and method of cancer antigen immunotherapy

47
Priority: Oct 5, 1999Filed: Jul 5, 2001Published: Jan 17, 2002
Est. expiryOct 5, 2019(expired)· nominal 20-yr term from priority
Inventors:Gary Wood
A61K 2039/55522A61K 40/428A61K 40/414A61K 40/11A61K 2239/56A61K 2239/49A61K 2239/38A61K 2239/47A61P 35/00
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A cancer immunotherapy method and composition for treating cancer in a patient comprised of vaccinating a patient with a vaccine comprised of the patient's own malignancy and an immunologic adjuvant, removing primed peripheral blood T lymphocytes from the patient, stimulating the primed T lymphocytes to differentiate into effector lymphocytes in vitro, stimulating the effector T lymphocytes to proliferate in vitro, and infusing the effector T lymphocytes back into the patient.

Claims

exact text as granted — not AI-modified
I claim:  
     
         1 . A cancer immunotherapy method for treating cancer in a patient comprising: 
 a. vaccinating a patient with a vaccine comprised of the patient's own malignancy and an immunologic adjuvant;    b. removing primed peripheral blood T lymphocytes from the patient;    c. stimulating the primed T lymphocytes to differentiate into effector lymphocytes in vitro;    d. stimulating the effector T lymphocytes to proliferate in vitro; and    e. infusing the effector T lymphocytes back into the patient.    
     
     
         2 . The cancer immunotherapy method in  claim 1  wherein the immunologic adjuvant is GM-CSF.  
     
     
         3 . The cancer immunotherapy method in  claim 1  wherein the removal step is performed by leukapheresis.  
     
     
         4 . The cancer immunotherapy method in  claim 1  wherein the differentiation step is performed using anti-CD3.  
     
     
         5 . The cancer immunotherapy method in  claim 1  wherein the proliferating step is performed using IL-2.  
     
     
         6 . The cancer immunotherapy method in  claim 1  wherein the cancer immunotherapy is directed to the treatment of breast cancer.  
     
     
         7 . The cancer immunotherapy method in  claim 1  wherein the cancer immunotherapy is directed to the treatment of astrocytoma.  
     
     
         8 . The cancer immunotherapy method in  claim 1  wherein the cancer immunotherapy is directed to the treatment of renal cancer.  
     
     
         9 . The cancer immunotherapy method in  claim 1  wherein the patient is v accinated at multiple body sites.  
     
     
         10 . The cancer immunotherapy method in  claim 1  wherein the patient is treated at the time of initial diagnosis.  
     
     
         11 . The cancer immunotherapy method in  claim 1  wherein the patient is treated immediately following surgical removal of cancer.  
     
     
         12 . The cancer immunotherapy method in  claim 1  wherein the patient is treated with subpopulations of activated peripheral blood T lymphocytes.  
     
     
         13 . A method of manufacturing a composition comprised of effector T lymphocytes generated by: 
 a. vaccinating a patient with a vaccine comprised of the patient's own malignancy and an immunologic adjuvant;    b. removing primed peripheral blood T lymphocytes from the patient;    c. stimulating the primed T lymphocytes to differentiate into effector lymphocytes in vitro; and    d. stimulating the effector T lymphocytes to proliferate in vitro.    
     
     
         14 . The method in  claim 13  wherein the immunologic adjuvant is GM-CSF.  
     
     
         15 . The method in  claim 13  wherein the removal step is performed by leukapheresis.  
     
     
         16 . The method in  claim 13  wherein the differentiation step is performed using anti-CD3.  
     
     
         17 . The method in  claim 13  wherein the proliferating step is performed using IL-2.  
     
     
         18 . A composition comprised of effector T lymphocytes made by the process of: 
 a. vaccinating a patient with a vaccine comprised of the patient's own malignancy and an immunologic adjuvant;    b. removing primed peripheral blood T lymphocytes from the patient;    c. stimulating the primed T lymphocytes to differentiate into effector lymphocytes in vitro; and    d. stimulating the effector T lymphocytes to proliferate in vitro.    
     
     
         19 . The method in  claim 18  wherein the immunologic adjuvant is GM-CSF.  
     
     
         20 . The method in  claim 18  wherein the removal step is performed by leukapheresis.  
     
     
         21 . The method in  claim 18  wherein the differentiation step is performed using anti-CD 3.  
     
     
         22 . The method in  claim 18  wherein the proliferating step is performed using IL-2.

Join the waitlist — get patent alerts

Track US2002006409A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.